"Our results are highly promising, especially since currently there are no approved treatments that address the underlying cause of Dravet syndrome. Since this gene regulation product targets the actual root cause of Dravet syndrome, we observed improvements in other developmental and cognitive symptoms, in addition to seizure control. This is unprecedented."
"A first‑ever gene‑regulation therapy tested in early‑phase clinical trials co‑led by Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago's Linda Laux, MD, has proven safe. The drug, called zorevunersen, delivered striking improvements in seizure frequency, language, motor skills and behavior, the study found, marking a potential turning point for patients whose conditions have long resisted standard treatment."
"Dravet syndrome includes a spectrum of symptoms that emerge in infancy and evolve. Most patients experience cognitive deficits, communication and behavioral impairments, motor dysfunction, growth delays and autistic traits. Difficulties with feeding, poor appetite and weight loss are also common."
Dravet syndrome is a severe epileptic disorder emerging in infancy with symptoms including frequent seizures, cognitive deficits, communication impairments, motor dysfunction, and autistic traits. Early-phase clinical trials of zorevunersen, a gene-regulation therapy, show the drug is safe and produces significant improvements in seizure frequency, language, motor skills, and behavior. Unlike current treatments that only manage symptoms, zorevunersen targets the root genetic cause by addressing SCN1A gene mutations. Benefits persisted in follow-up studies where participants continued treatment. This represents a potential breakthrough for patients whose conditions have resisted conventional therapies.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]